Tag: <span>restrict coverage</span>

Home / restrict coverage
Post

CMS to restrict coverage of Biogen’s controversial Alzheimer’s drug to only clinical trials

by ZACHARY BRENNAN CMS on Tuesday said it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials. In a draft national coverage decision, which insurers nationwide are likely to follow, CMS said it’ll be looking for randomized controlled trials that “demonstrate a clinically meaningful benefit in cognition...